

Special Issue

Advances in Small-Molecule Therapeutics Targeting Signaling Pathways

Message from the Guest Editor

This Special Issue of *Pharmaceuticals* dedicated to *Advances in Small-Molecule Therapeutics Targeting Signaling Pathways* concerns the involvement of the signaling pathways in the pathophysiological mechanisms of various human diseases (diabetes, cancer, etc.), focusing on the modulating role of small molecules. The aim is to address the current trends and outcomes in drug research and development, while also considering the integration of important innovative approaches with conventional ones. Examples of these techniques include the application of artificial intelligence technology and structural biology techniques, as well as the evolution of sequencing technology and nanotechnology. Currently, although they present several challenges, these new technologies are promising not only for strengthening drug discovery but also for broadening the target range, possibly including areas that are undruggable. This Special Issue is expected to contribute as a source of innovative and original research articles, as well as perspective papers and reviews.

Guest Editor

Dr. Arianna Gelain

Department of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milano, Italy

Deadline for manuscript submissions

30 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/227329

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)